Relugolix Plus Enzalutamide For Metastatic Hormone-Sensitive Prostate Cancer: A Case Report.

IF 2 Q2 UROLOGY & NEPHROLOGY

Research and Reports in Urology Pub Date : 2024-10-09 eCollection Date: 2024-01-01 DOI:10.2147/RRU.S485238

Alastair Thomson, Lucinda Gunn, Deborah Victor, Ellis Adamson, Kashyap Thakrar

{"title":"Relugolix Plus Enzalutamide For Metastatic Hormone-Sensitive Prostate Cancer: A Case Report.","authors":"Alastair Thomson, Lucinda Gunn, Deborah Victor, Ellis Adamson, Kashyap Thakrar","doi":"10.2147/RRU.S485238","DOIUrl":null,"url":null,"abstract":"Background: In the UK, relugolix, an oral gonadotropin-releasing hormone receptor antagonist, is indicated for advanced hormone-sensitive prostate cancer, and as neo-adjuvant and adjuvant treatment in combination with radiotherapy in patients with high-risk localised or locally advanced hormone-dependent prostate cancer. Experience with the combination of oral relugolix plus oral enzalutamide is limited.Case presentation: A white British male (66 years old) with a history of myelodysplastic syndrome, chronic neutropenia and indeterminate colitis presented with metastatic adenocarcinoma of the prostate gland. The patient started subcutaneous leuprorelin acetate and oral enzalutamide. After 8 weeks, the oral enzalutamide dose was reduced because of fatigue. Following the second leuprorelin injection, the patient developed a subcutaneous abscess that required surgical incision and drainage. The patient switched to oral relugolix and continued with oral enzalutamide. Within 3 months of commencing leuprorelin and enzalutamide the prostate specific antigen (PSA) concentration fell from a peak of 269.00 ng/mL to 2.55 ng/mL. Following the switch to oral relugolix plus enzalutamide, the PSA remained stable until the most recent assessment 11 months later. Relugolix plus enzalutamide was well tolerated.Conclusion: Relugolix plus enzalutamide produced a sustained reduction in PSA and the combination was well tolerated. Further research including real world data should assess relugolix in doublet and triplet combinations for prostate cancer.","PeriodicalId":21008,"journal":{"name":"Research and Reports in Urology","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11471072/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research and Reports in Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/RRU.S485238","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: In the UK, relugolix, an oral gonadotropin-releasing hormone receptor antagonist, is indicated for advanced hormone-sensitive prostate cancer, and as neo-adjuvant and adjuvant treatment in combination with radiotherapy in patients with high-risk localised or locally advanced hormone-dependent prostate cancer. Experience with the combination of oral relugolix plus oral enzalutamide is limited.

Case presentation: A white British male (66 years old) with a history of myelodysplastic syndrome, chronic neutropenia and indeterminate colitis presented with metastatic adenocarcinoma of the prostate gland. The patient started subcutaneous leuprorelin acetate and oral enzalutamide. After 8 weeks, the oral enzalutamide dose was reduced because of fatigue. Following the second leuprorelin injection, the patient developed a subcutaneous abscess that required surgical incision and drainage. The patient switched to oral relugolix and continued with oral enzalutamide. Within 3 months of commencing leuprorelin and enzalutamide the prostate specific antigen (PSA) concentration fell from a peak of 269.00 ng/mL to 2.55 ng/mL. Following the switch to oral relugolix plus enzalutamide, the PSA remained stable until the most recent assessment 11 months later. Relugolix plus enzalutamide was well tolerated.

Conclusion: Relugolix plus enzalutamide produced a sustained reduction in PSA and the combination was well tolerated. Further research including real world data should assess relugolix in doublet and triplet combinations for prostate cancer.

查看原文本刊更多论文

Relugolix 加 Enzalutamide 治疗转移性激素敏感性前列腺癌：病例报告。

背景：在英国，口服促性腺激素释放激素受体拮抗剂瑞格列奈（relugolix）适用于晚期激素敏感性前列腺癌，也可作为高危局部或局部晚期激素依赖性前列腺癌患者的新辅助治疗和辅助治疗，并与放疗相结合。口服瑞格列奈加口服恩杂鲁胺的联合用药经验有限：病例介绍：一名英国白人男性（66 岁），曾患骨髓增生异常综合征、慢性中性粒细胞减少症和不确定结肠炎，并伴有前列腺转移性腺癌。患者开始皮下注射醋酸亮丙瑞林和口服恩杂鲁胺。8周后，由于疲劳，口服恩杂鲁胺的剂量减少。第二次注射亮丙瑞林后，患者出现皮下脓肿，需要手术切开引流。患者改用口服瑞格列奈，并继续口服恩杂鲁胺。在开始服用利普瑞林和恩杂鲁胺的3个月内，前列腺特异性抗原（PSA）浓度从峰值269.00纳克/毫升降至2.55纳克/毫升。改用口服瑞格列奈加恩扎鲁胺后，PSA一直保持稳定，直到11个月后的最近一次评估。瑞谷力加恩杂鲁胺的耐受性良好：结论：Relugolix 加恩杂鲁胺可持续降低 PSA，且该组合的耐受性良好。包括真实数据在内的进一步研究应评估relugolix在前列腺癌治疗中的双药和三药组合。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Research and Reports in Urology UROLOGY & NEPHROLOGY-

CiteScore

3.40

自引率

0.00%

发文量

审稿时长

16 weeks

期刊介绍： Research and Reports in Urology is an international, peer-reviewed, open access, online journal. Publishing original research, reports, editorials, reviews and commentaries on all aspects of adult and pediatric urology in the clinic and laboratory including the following topics: Pathology, pathophysiology of urological disease Investigation and treatment of urological disease Pharmacology of drugs used for the treatment of urological disease Although the main focus of the journal is to publish research and clinical results in humans; preclinical, animal and in vitro studies will be published where they will shed light on disease processes and potential new therapies. Issues of patient safety and quality of care will also be considered.